MGD-Meibomian Gland DysfunctionNCT06324890
PET-CT Imaging Features of Meibomian Glands
An observational study of MGD-Meibomian Gland Dysfunction and Positron-Emission Tomography, run by Zhongnan Hospital at 1 site in China.
Trial summary
Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- MGD-Meibomian Gland Dysfunction, Positron-Emission Tomography, Dry Eye
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 31 Jan 2024to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients who visited the ophthalmology Department of Zhongnan Hospital from January 2021 to December 2023 and had a PET-CT examination in the hospital within one month
Who may be able to join
- Patients who visited the ophthalmology Department of Zhongnan Hospital from January 2021 to December 2023 and had a PET-CT examination in the hospital within one month
Who cannot join
- Dry eye analysis was not performed
- History of eye surgery or trauma
- Other systemic diseases affecting the eyes
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071
Min Ke, Doctor, +86-18672395959, keminyk@163.com
About this study
Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively
Read the detailed description
Medical records of patients who visited the ophthalmology department between January 2021 and December 2023 and had a PET-CT examination in our hospital within one month were collected. The dry eye analysis results of all patients were collected, and the lacrimal river height, tear film rupture time and meibomian gland grade were counted. The results of PET-CT were collected and the SUV values of the tarsal gland were calculated.
- Medical subject headings
- Meibomian Gland Dysfunction, Dry Eye Syndromes
What is being measured
The primary outcome is the main question the study is designed to answer.
Lacrimal river height
Measured by dry eye analyzer machine
Measured: Within a month of the PET imaging
Tear break-up time
Measured by dry eye analyzer machine
Measured: Within a month of the PET imaging
Tear-film lipid layer thickness
Measured by dry eye analyzer machine
Measured: Within a month of the PET imaging
Meibomian glands two-dimensional digital infrared images
Measured by dry eye analyzer machine
Measured: Within a month of the PET imaging
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2024
- Study start31 Jan 2024
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MGD-Meibomian Gland DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhongnan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06324890
- Sponsor's protocol ID
- 20240225
- Status last verified
- Feb 2024
- First submitted
- 27 Feb 2024
- Last updated
- 22 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PET-CT Imaging Features of Meibomian Glands
- ClinicalTrials.gov ID
- NCT06324890
- Acronym / sponsor ID
- 20240225
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Zhongnan HospitalUniversity, hospital or other
- Study start
- 31 Jan 2024 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 22 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively
Detailed description
Medical records of patients who visited the ophthalmology department between January 2021 and December 2023 and had a PET-CT examination in our hospital within one month were collected. The dry eye analysis results of all patients were collected, and the lacrimal river height, tear film rupture time and meibomian gland grade were counted. The results of PET-CT were collected and the SUV values of the tarsal gland were calculated.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients who visited the ophthalmology Department of Zhongnan Hospital from January 2021 to December 2023 and had a PET-CT examination in the hospital within one month
Key inclusion criteria (1 listed)
- Patients who visited the ophthalmology Department of Zhongnan Hospital from January 2021 to December 2023 and had a PET-CT examination in the hospital within one month
Key exclusion criteria (3 listed)
- Dry eye analysis was not performed
- History of eye surgery or trauma
- Other systemic diseases affecting the eyes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Lacrimal river height
Time frame: Within a month of the PET imaging
Measured by dry eye analyzer machine
Tear break-up time
Time frame: Within a month of the PET imaging
Measured by dry eye analyzer machine
Tear-film lipid layer thickness
Time frame: Within a month of the PET imaging
Measured by dry eye analyzer machine
Meibomian glands two-dimensional digital infrared images
Time frame: Within a month of the PET imaging
Measured by dry eye analyzer machine
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Mar 2024.
Related trials for MGD-Meibomian Gland Dysfunction
Active, not recruiting
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
Meibomian Gland Dysfunction, Dry Eye Disease
Not yet recruiting
TearCare in Young Adults
Meibomian Gland Dysfunction (Disorder)
Active, not recruitingPhase 2
Autologous Serum Obtained by a Closed-Circuit Collection Device
GVHD, Meibomian Gland Dysfunction (Disorder)
Not yet recruitingObservational study
Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients
Meibomian Gland Dysfunction, Dry Eye Syndromes
Enrolling by invitation
Microbiome-Focused Food Supplement for Evaporative Dry Eye Due to Meibomian Gland Dysfunction
Dry Eye, Evaporative Dry Eye Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of MGD-Meibomian Gland Dysfunction and Positron-Emission Tomography, run by Zhongnan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lacrimal river height (time frame: Within a month of the PET imaging). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2024.